Published in Women's Health Weekly, July 6th, 2006
"Most women with estrogen receptor (ER) positive primary breast cancer receive adjuvant tamoxifen after surgery. The measurement of tumor biomarkers should allow better selection of patients for such treatment or for therapies such as aromatase inhibitors," investigators in England report.
M. Dowsett and colleagues, Royal Marsden NHS Trust, said, "Histopathological blocks of primary breast cancer patients who had been randomized to receive 2-years tamoxifen or no adjuvant therapy in 2 mature randomized clinical trials were retrieved....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly